British American Tobacco (LON: BATS) can now test Covid vaccine on humans

 

 British American Tobacco has been given the go-ahead to test the Covid vaccine testing on humans in the US. The US Food & Drug Administration has allowed the company to start its clinical study with adult volunteers.

  • BAT has previously said that it can produce its own vaccine in six weeks, compared with others taking several months in doing that.
  • BAT has also said that its vaccine is more stable at room temperature, unlike the Pfizer vaccine, which requires a temperature of below 70c.
  • Kentucky BioProcessing (KBP), the biotechnology division of the company has been developing the vaccine alongside a seasonal flu vaccine. It had earlier worked on a treatment for Ebola.
  • KBP has claimed that it can turn tobacco plants into “bio-manufacturing factories” capable of producing proteins.
  • As per British American Tobacco, for the Covid-19 vaccine, KBP had cloned a part of the genetic sequence of coronavirus and created a prospective antigen, which is then injected into tobacco plants for breeding.
  • Reacting to the development, director of scientific research for BAT, Dr David O’Reilly said that the approval for human trial for both the Covid-19 and the seasonal flu vaccine is a big achievement and portrays the company’s growing reach in emerging biologicals portfolio.
  • The stocks of British American Tobacco Plc (LON: BATS) on 17 December 2020, traded lower by 2.57% from its previous closing, hovering at around GBX 2,786.50 at 14:29 PM GMT+1.

Disclaimer
The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is not authorised or regulated by the Financial Conduct Authority to provide regulated advice. The purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. The Content is guidance about the different types of investments that are available and sets out general principles to continue before making investment decisions. Kalkine Media is neither authorised nor qualified to provide regulated investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from an appropriately authorised and/or qualified financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.